Accuray Incorporated (NASDAQ:ARAY) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in Accuray Incorporated (NASDAQ:ARAY) by 104.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,680 shares of the medical equipment provider’s stock after acquiring an additional 23,808 shares during the quarter. Intech Investment Management LLC’s holdings in Accuray were worth $92,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Accuray by 3.8% in the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after purchasing an additional 70,008 shares during the period. Barclays PLC lifted its position in shares of Accuray by 97.9% during the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock valued at $380,000 after acquiring an additional 104,310 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Accuray by 1,650.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock worth $263,000 after acquiring an additional 138,022 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 230,695 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Accuray by 28.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider’s stock valued at $420,000 after purchasing an additional 47,331 shares in the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Accuray Stock Performance

Shares of ARAY opened at $1.89 on Friday. The company has a 50-day moving average of $2.09 and a two-hundred day moving average of $1.99. The stock has a market cap of $194.35 million, a P/E ratio of -37.80 and a beta of 1.46. Accuray Incorporated has a 12-month low of $1.40 and a 12-month high of $2.95. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. As a group, research analysts predict that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com raised Accuray from a “hold” rating to a “buy” rating in a report on Saturday, March 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.